Raleigh’s Aceragen, Arrevus Combine Forces to Tackle Rare Diseases

Raleigh-based Aceragen, a biopharmaceutical company developing therapeutics for rare and orphan diseases, has acquired Arrevus, another Raleigh company with a similar focus.